Oct 14, 2026
AllerGene AI Therapeutics Founder and CEO Dr. Sid Kerkar speaks with Technology Networks about the personal experience that led him to explore in vivo CAR-T for severe allergies. He explains how targeted lipid nanoparticles delivering short-lived mRNA could temporarily program T cells to remove mast cells, the cells at the center of allergic reactions. The interview also covers why transient CAR expression suits chronic, non-malignant disease, and how in vivo engineering compares with traditional CAR-T therapy.
Aug 19, 2026
AllerGene AI Therapeutics Founder and CEO Dr. Sid Kerkar discusses how gene therapy and in vivo CAR-T technology could help address the root cause of severe food allergies by targeting mast cells. In this episode of the Empowered Patient Podcast, Dr. Kerkar shares insights into AllerGene AI’s innovative approach to developing potential treatments for food allergies, allergic asthma, chronic urticaria, mastocytosis, and anaphylaxis.
July 21, 2026
Founder and CEO Sid Kerkar, M.D., will present AllerGene’s in vivo mRNA-LNP CAR-T platform at Hanson Wade’s 5th In Vivo Cell Engineering & Gene Editing Summit, July 28–30, 2026, in Boston. His talk, scheduled for July 30 at 11:00 a.m., will cover the company’s approach to engineering CAR-T cells directly in the body to selectively target disease-driving mast cells — a potential new treatment path for mastocytosis, chronic urticaria, food allergies, allergic asthma, and anaphylaxis.
July 21, 2026
Founder and CEO Sid Kerkar, M.D., will present AllerGene’s in vivo mRNA-LNP CAR-T platform at Hanson Wade’s 5th In Vivo Cell Engineering & Gene Editing Summit, July 28–30, 2026, in Boston. His talk, scheduled for July 30 at 11:00 a.m., will cover the company’s approach to engineering CAR-T cells directly in the body to selectively target disease-driving mast cells — a potential new treatment path for mastocytosis, chronic urticaria, food allergies, allergic asthma, and anaphylaxis.
June 9, 2026
Gad Berdugo, MSc Eng., MBA, joins as an independent board member in connection with an investment from Explorium Capital LLC through the Cane Angel Network. He brings over 30 years of leadership in biotechnology, RNA therapeutics, and capital markets — including senior roles at Editas Medicine, Abbott Laboratories, and Baxter International.